Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Jun 30;15(3):1358-1362.
doi: 10.21037/jgo-24-224. Epub 2024 Apr 25.

Emerging role of circulating tumor DNA for early detection of recurrence in biliary tract cancers

Matthew D Bloom  1 , Babar Bashir  1   2
Affiliations
Editorial

Emerging role of circulating tumor DNA for early detection of recurrence in biliary tract cancers

Matthew D Bloom et al. J Gastrointest Oncol. .
No abstract available

Keywords: Cholangiocarcinoma (CCA); bile duct cancer; circulating tumor DNA (ctDNA); immunotherapy; microsatellite instability (MSI).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://jgo.amegroups.com/article/view/10.21037/jgo-24-224/coif). B.B. is supported by the Defense Congressionally Directed Medical Research Program # W81XWH-22-1-0208. B.B. served on advisory board for Merck/Eisai, Fate Therapeutics and KAHR Medical. B.B. reports research funding to institution from Amgen, Inc., Boehringer Ingelheim, Bicycle Therapeutics, Elucida Oncology, Gritstone Bio, Ikena Oncology, Jazz Pharmaceuticals, KAHR Medical, Lyell immunopharma, Merck, PionyrImmunopharma, Rascal Therapeutics, Syros Pharmaceuticals, Tarveda Therapeutics, all outside the submitted work. The other author has no conflicts of interest to declare.

Comment on

References

    1. Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol 2020;17:557-88. 10.1038/s41575-020-0310-z - DOI - PMC - PubMed
    1. Moris D, Palta M, Kim C, et al. Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians. CA Cancer J Clin 2023;73:198-222. 10.3322/caac.21759 - DOI - PubMed
    1. Bridgewater J, Fletcher P, Palmer DH, et al. Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study. J Clin Oncol 2022;40:2048-57. 10.1200/JCO.21.02568 - DOI - PubMed
    1. Benson AB, D'Angelica MI, Abrams T, et al. NCCN Guidelines® Insights: Biliary Tract Cancers, Version 2.2023. J Natl Compr Canc Netw 2023;21:694-704. 10.6004/jnccn.2023.0035 - DOI - PubMed
    1. Reinert T, Henriksen TV, Christensen E, et al. Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer. JAMA Oncol 2019;5:1124-31. 10.1001/jamaoncol.2019.0528 - DOI - PMC - PubMed

LinkOut - more resources